In a double-blind, randomized cross-over study the antianginal efficacy and tolerability of Elantan® Long (50 mg sustained-release IS-5-MN) were compared with a 80-mg sustained-release (s.r.) IS-5-MN formulation. 28 patients were enrolled in the study, which consisted of a 3-day washout period on placebo, an active treatment of 14 days (crossover after 7 days) and a final 3-day withdrawal period on placebo. Ergometric exercise tests with simultaneous ECG monitoring were carried out 2 and 10 h post administration (p.a.) on the last days of each period. Under 50 mg s.r. IS-5-MN the mean ST- segment depression under comparable load was reduced by 67% 2 h p.a. and by 70% 10 h p.a. The reduction under the 80 mg IS-5-MN form was about 76% 2 h p.a. and 78% 10 h p.a. Maximum workload, working capacity, duration of exercise, time to angina pectoris and time to ST-segment depression > 0.1 mV were markedly increased under therapy with each dosage. Comparisons between the medications revealed significant differences only in time to ST-segment depression > 0.1 mV and in ST-segment depression under maximum workload at 10 h p.a. which were increased more by the higher dosage. The incidence
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً